SARS-CoV-2 感染和 COVID-19 疾病的保护相关因素。
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
机构信息
Great Ormond Street Institute of Child Health, University College London, London, UK.
Massachusetts General Hospital, Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
出版信息
Immunol Rev. 2022 Sep;310(1):6-26. doi: 10.1111/imr.13091. Epub 2022 Jun 5.
Abstract
Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS-CoV-2 coronavirus. Measurement of those antibodies by neutralization or binding assays both have predictive value, with binding antibody titers giving the highest statistical correlation. However, the protective functions of antibodies are multiple. Antibodies with multiple functions other than neutralization influence efficacy. The role of cellular responses can be discerned with respect to CD4 T cells and their augmentation of antibodies, and with respect to CD8 cells with regard to control of viral replication, particularly in the presence of insufficient antibody. More information is needed on mucosal responses.
摘要
针对 S1 表位的抗体对感染 SARS-CoV-2 冠状病毒提供了最准确的保护作用。通过中和或结合测定法测量这些抗体都具有预测价值，其中结合抗体滴度具有最高的统计学相关性。然而，抗体的保护功能是多方面的。除中和作用以外具有多种功能的抗体影响疗效。可以从 CD4 T 细胞及其对抗体的增强作用以及 CD8 细胞对病毒复制的控制作用方面来识别细胞反应的作用，特别是在抗体不足的情况下。还需要更多关于黏膜反应的信息。
相似文献
1
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
Immunol Rev. 2022 Sep;310(1):6-26. doi: 10.1111/imr.13091. Epub 2022 Jun 5.
2
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
Microbiol Spectr. 2022 Feb 23;10(1):e0267621. doi: 10.1128/spectrum.02676-21. Epub 2022 Jan 26.
3
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
4
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Nat Immunol. 2021 Dec;22(12):1503-1514. doi: 10.1038/s41590-021-01068-z. Epub 2021 Oct 29.
5
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies.
Trends Immunol. 2024 Aug;45(8):609-624. doi: 10.1016/j.it.2024.06.003. Epub 2024 Jul 20.
6
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
mBio. 2021 Dec 21;12(6):e0297521. doi: 10.1128/mBio.02975-21. Epub 2021 Nov 16.
7
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
MAbs. 2021 Jan-Dec;13(1):1893426. doi: 10.1080/19420862.2021.1893426.
8
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
mSphere. 2021 Feb 24;6(1):e01145-20. doi: 10.1128/mSphere.01145-20.
9
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
PLoS Pathog. 2024 Jun 20;20(6):e1011569. doi: 10.1371/journal.ppat.1011569. eCollection 2024 Jun.
10
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Immunity. 2021 Jun 8;54(6):1276-1289.e6. doi: 10.1016/j.immuni.2021.03.023. Epub 2021 Apr 1.
引用本文的文献
1
Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos.
Vaccines (Basel). 2025 Jul 22;13(8):776. doi: 10.3390/vaccines13080776.
2
Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses.
Front Immunol. 2025 Aug 4;16:1603612. doi: 10.3389/fimmu.2025.1603612. eCollection 2025.
3
Pregnancy reduces COVID-19 vaccine immunity against novel variants.
NPJ Vaccines. 2025 Aug 13;10(1):191. doi: 10.1038/s41541-025-01236-4.
4
Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity.
PLoS Pathog. 2025 Aug 6;21(8):e1013408. doi: 10.1371/journal.ppat.1013408. eCollection 2025 Aug.
5
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.
J Med Virol. 2025 Aug;97(8):e70521. doi: 10.1002/jmv.70521.
6
SARS-CoV-2 vaccines elicit differential Fc effector functions.
iScience. 2025 Jul 9;28(8):113084. doi: 10.1016/j.isci.2025.113084. eCollection 2025 Aug 15.
7
SARS-CoV-2 mRNA vaccines confer protection in diet-induced obese mice despite altered immune cell profiles in the lung.
Sci Rep. 2025 Jul 26;15(1):27209. doi: 10.1038/s41598-025-12320-z.
8
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S57-S65. doi: 10.1093/cid/ciaf095.
9
Immunogenicity of COVID-19 booster vaccines in children receiving immunosuppressive medications.
Pediatr Res. 2025 Jul 21. doi: 10.1038/s41390-025-04174-y.
10
Anti-SARS-CoV-2 Antibody Levels in a Cohort of Health Care Workers Before and After the Omicron Wave in Canada.
J Assoc Med Microbiol Infect Dis Can. 2025 May 29;10(2):127-145. doi: 10.3138/jammi-2024-0029. eCollection 2025 Jun.
本文引用的文献
1
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
PLoS One. 2022 Oct 18;17(10):e0263861. doi: 10.1371/journal.pone.0263861. eCollection 2022.
2
Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.
Nat Microbiol. 2022 Jul;7(7):974-985. doi: 10.1038/s41564-022-01161-5. Epub 2022 Jun 9.
3
Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection.
Mucosal Immunol. 2022 May;15(5):799-808. doi: 10.1038/s41385-022-00511-0. Epub 2022 Apr 25.
4
Mucosal Antibody Response to SARS-CoV-2 in Paediatric and Adult Patients: A Longitudinal Study.
Pathogens. 2022 Mar 24;11(4):397. doi: 10.3390/pathogens11040397.
5
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
Cell. 2022 Apr 28;185(9):1549-1555.e11. doi: 10.1016/j.cell.2022.03.024. Epub 2022 Mar 17.
6
Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.
Clin Immunol. 2022 Apr;237:108991. doi: 10.1016/j.clim.2022.108991. Epub 2022 Mar 29.
7
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
Nat Med. 2022 May;28(5):1031-1041. doi: 10.1038/s41591-022-01780-9. Epub 2022 Mar 31.
8
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.
Sci Transl Med. 2022 May 18;14(645):eabm2311. doi: 10.1126/scitranslmed.abm2311.
9
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant.
Sci Transl Med. 2022 Apr 20;14(641):eabn6150. doi: 10.1126/scitranslmed.abn6150.
10
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
Zotero 插件